Axogen vs MiMedx
AXGN and MDXG side by side, both in surgical, medical, and dental instruments and supplies. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How AXGN and MDXG compare
Axogen is the larger company, worth 7.1 times as much as MiMedx ($3.3B against $468M).
Axogen grew revenue faster over the last twelve months (24.3% versus −22.8% for MiMedx).
MiMedx keeps more of each dollar of sales as profit, with a net margin of −6.3% compared with −12.0% at Axogen.
MiMedx scores higher on the StockData Score (12 against 11 for Axogen), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | AXGN | MDXG |
|---|---|---|
| Size and price | ||
| Market cap | $3.3B | $468M |
| Share price | $55.93 | $3.21 |
| Change, 1 year | 132% | −57.1% |
| Change, 5 years | 473% | −58.5% |
| Beta (5Y) | 1.16 | 0.97 |
| Employees | 622 | 808 |
| StockData Score | ||
| Total score | 11 | 12 (better) |
| Valuation score | 0 | 3 (better) |
| Growth score | 3 (better) | 1 |
| Performance score | 3 (better) | 2 |
| Health score | 5 | 6 (better) |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/S | 12.5× | 1.5× (better) |
| P/B | 6.7× | 2.2× (better) |
| P/FCF | 152× | – |
| FCF yield | 0.66% | – |
| Fair value | $22.93 | $4.85 |
| Margin of safety | −144% | 33.8% (better) |
| Growth | ||
| Revenue growth (TTM) | 24.3% (better) | −22.8% |
| Revenue growth, 5Y average | 14.9% (better) | 11.0% |
| Net income growth (TTM) | – | −147% |
| EPS growth (TTM) | – | −148% |
| Profitability | ||
| Gross margin | 74.2% | 77.3% (better) |
| Operating margin | −5.2% (better) | −8.3% |
| Net margin | −12.0% | −6.3% (better) |
| FCF margin | 8.3% | – |
| Return on equity | −10.3% | −8.5% (better) |
| Return on invested capital | −7.9% (better) | −19.3% |
| Financial health | ||
| Debt / equity | 0.00 | 0.00 |
| Interest coverage | −5.7× | – |
| Current ratio | 12.02 (better) | 4.35 |
| Altman Z-score | 37.41 (better) | 6.34 |
| Piotroski F-score | 5 | 6 (better) |
| Dividends and buybacks | ||
| Shareholder yield | 0.00% | 0.00% |
| Ownership | ||
| Held by institutions | 90.4% | 79.9% |
| Held by insiders | 7.6% | 2.9% |
| Insider net buying, 12 months | −$17.1M | $0 (better) |
| Short interest, % of float | 12.7% | 6.3% |
Go deeper
- AXGN stock overview
- AXGN income statement
- AXGN valuation and score
- MDXG stock overview
- MDXG income statement
- MDXG valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.